Safety and Efficacy of Eliglustat with or without Imiglucerase in Pediatric Patients with Gaucher Disease (GD) Type 1 and Type 3

Trial Identifier: EFC13738
Sponsor: Sanofi
Start Date: April 2018
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Gaucher Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA, Buenos Aires Capital Federal, Buenos Aires, ARGENTINA, C1425DUC
CANADA, Alberta Calgary, Alberta, CANADA, T3B 6A8
CANADA, British Columbia Vancouver, British Columbia, CANADA, V6H 3V4
CANADA, Ontario Toronto, Ontario, CANADA, M5G 1X8
FRANCE BRON Cedex, FRANCE, 69677
ITALY, Roma Roma, ITALY, 00165
JAPAN, Saitama Koshigaya-shi, Saitama, JAPAN, 343-8555
JAPAN, Tokyo Minato-ku, Tokyo, JAPAN, 105-8471
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119049
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119991
RUSSIAN FEDERATION St-Petersburg, RUSSIAN FEDERATION, 197341
RUSSIAN FEDERATION Tomsk, RUSSIAN FEDERATION, 634050
SPAIN, Bizkaia Barakaldo, Bizkaia, SPAIN, 48903
SPAIN, Catalunya [Cataluña] Esplugues de Llobregat, Catalunya [Cataluña], SPAIN, 08950
SPAIN, Zaragoza Zaragoza, SPAIN, 50006
SWEDEN Göteborg, SWEDEN, 416 85
SWEDEN Luleå, SWEDEN, 97180
Turkey Adana, Turkey, 01300
Turkey Istanbul, Turkey, 34093
Turkey Izmir, Turkey, 35040
UNITED KINGDOM, Not Known Birmingham, Not Known, UNITED KINGDOM, B4 6NH